NIKI Stock — Niki BioSolutions, Inc.

Niki BioSolutions, Inc. (NIKI)

Updated October 16, 2026.

NIKI is a Stock. Total return is -77.0% over the past 0.2 years, 80.1 points behind SPY at 3.1%.

Niki BioSolutions is a clinical-stage biopharmaceutical company developing therapeutic candidates for oncology and infectious diseases, with its pipeline including SACT-1 in Phase 1 trials for neuroblastoma, ALS-4 in Phase 1 trials for bacterial infections, and several preclinical-stage programs. As a pre-revenue development-stage company with no established dividend history, it does not currently distribute to shareholders. This security appeals primarily to investors seeking exposure to early-stage drug development with high risk and potential for long-term capital appreciation rather than current income.

NIKI performance versus SPY

Price and return data through 2026-10-16.

Total return is -77.0% over the past 0.2 years, 80.1 points behind SPY at 3.1%.

NIKI key facts

Asset type

Stock

Asset class

Equity

Inception date

07/20/2026

Distribution frequency

None

Last close

$2.03 (as of 2026-10-16)

Market cap

$5,965,409

Average volume

24900.0

Beta

-0.996

Payout ratio

0.0%

EPS

$-2.90

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NIKI risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider NIKI — and who may not

It is a weaker fit for investors who need monthly cash flow (NIKI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NIKI

• All tickers starting with N

Frequently asked questions